Alan Mendelsohn, MD, Chief Medical Officer at Timber Pharmaceuticals, discusses the mechanism of action of TMB-001, an investigational treatment for congenital ichthyosis.
Congenital ichthyosis is a rare genetic skin disorder characterized by dry, thickened, and scaling skin. Individuals with this condition may experience limited range in motion, chronic itching, an inability to sweat, and increased risk of infections.
As Dr. Mendelsohn explains, TMB-001 is a topical isotretinoin that has been formulated using the Timber’s patented IPEG™ delivery system, for the treatment of moderate to severe forms of congenital ichthyosis. It is well known that retinoid therapy can play a crucial role in the treatment of congenital ichthyosis; however, the issue with retinoid therapies, particularly oral options, is their high toxicity when taken long-term. With that in mind, Timber Pharmaceuticals developed a retinoid therapy that could be applied topically to reduce toxicity and hopefully allow congenital ichthyosis patients to use the therapy for extended periods of time.
Timber Pharmaceuticals recently presented 7 abstracts at the 31st European Academy of Dermatology and Venereology Congress detailing positive clinical data from the completed phase 2b CONTROL study of TMB-001.
